Rostock, Germany, October 1, 2007 / b3c newswire/ - Bionas GmbH, a specialist for in vitro profiling of cellular metabolic activity, announced that it has signed a service contract with Solvay Pharmaceuticals GmbH (Hannover, Germany). The contract covers the metabolic profiling of several drug candidates identified in the context of Solvay´s obesity research program. Financial details were not disclosed.
Solvay has selected the Bionas® 2500 analyzing system because it allows monitoring of both acute (short-term) and chronic (long-term) effects of drug candidates in different cell types thanks to a proprietary perfusion system. Besides the long-term observation of cells under close to in vivo conditions, the observation of regeneration effects is also possible.
"The Bionas instrument is a valuable tool for compound ranking and helps us select the most promising compounds for further development," says Dr. Michael Firnges at Solvay Pharmaceuticals GmbH.
The Bionas® 2500 analyzing system is a bench-top instrument that allows the simultaneous, label-free and high-content analysis of three metabolic parameters, such as acidification, oxygen consumption and adhesion of living cells. The Bionas instrument has been also selected by Solvay Pharmaceuticals Research Laboratories (Weesp, Netherlands) for target validation studies.
About Bionas - www.bionas.de
Bionas GmbH, located in Rostock, Germany, specializes in analyzing systems and services for in vitro profiling the metabolic activity of cells to understand cellular function. Bionas® 2500 analyzing system measures extracellular acidification, oxygen consumption and cell adhesion label-free and noninvasively. It can be applied to various cell types including primary cells and tissues. The readout is performed continuously and can be monitored online. Main applications include drug profiling, lead optimization, pharmacokinetics, early toxicology programs, ADME/Tox, chemosensitivity testing, toxicological testing of chemical substances (REACH) and cell culture monitoring and optimization.
Contact at Bionas GmbH:
Dr. Michael Schulze
Managing Director
Tel.: +49 (0) 381 5196-241
email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Contact at Solvay Pharmaceuticals GmbH:
Sylvio Montag
Head of Communication, Germany
Tel.: +49 (0) 511 857 3079
email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Dr. Sabine Duntze
b3c communications
Tel.: +49 (0) 861 909 82 20
email: This email address is being protected from spambots. You need JavaScript enabled to view it.